nach oben

International Urology and Nephrology

Erschienen in:

01.04.2012 | Urology – Original Paper

Sexual function outcome following photoselective vaporisation of the prostate

verfasst von: Tania A. Hossack, Henry H. Woo

Erschienen in: International Urology and Nephrology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

There is little reported on sexual functional outcome following photoselective vaporisation of the prostate using the 120 W lithium triborate laser.

Objective

The objective of this study was to evaluate changes in sexual function at 3 and 12 months following PVP.

Material and Methods

The primary outcome measures were changes in voiding parameters and changes in erectile function in the international index of erectile function (IIEF-5). Change in erectile function was defined as mild (<5 IIEF points) or major (≥5 points).

Results

Results found that 75% of men had an IIEF-5 < 17 at baseline. At 3 months, the mean post-operative IIEF-5 score was unchanged compared to baseline (P = 0.13). A major decline in erectile function was seen in 12.4 and 24% of men at 3 and 12 months, respectively, and a major improvement in erectile function was seen in 8.3 and 6% at 3 and 12 months, respectively. There was no correlation in change in erectile function with urinary function, quality of life and loss of emission on orgasm. Loss of emission on orgasm was reported in 65% of respondents.

Conclusion

Significant changes in erectile function are observed following PVP although a cause and effect relationship remains unclear.

Richard F, Lukas B, Jardin A, Lanson Y, Navratil H (2000) Assessing sexual function and urinary symptoms: results of an epidemiological survey in 3,500 French men aged 50 to 80 years. J Urol 163:249–258CrossRef

Rosen RC, Wei JT, Althol SE, Seftel AD, Miner M, Perelman MA (2009) Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: result from the BPH registry. Urol 73:562–566PubMedCrossRef

Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL (2009) Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen study. J Urol 181:710–716PubMedCrossRef

Poulakis V, Ferakis N, Witzsch U, de Vries R, Becht E (2006) Erectile dysfunction after transurethral prostatectomy for lower urinary tract symptoms: results from a centre with over 500 patients. Asian J Urol 8:69–74

Soleimani M, Hosseine SY, Aliasgari M, Dadkhah F, Lashay A, Amini E (2009) Erectile dysfunction after prostatectomy: an evaluation of the risk factors. Scand J Urol Nephrol 43:277–281PubMedCrossRef

Rassweiler J, Teber D, Kuntz R, Hofman R (2006) Complications of transurethral resection of the prostate. Incidence, management and prevention. Eur Urol 50:969–979PubMedCrossRef

Mebust WK, Holthrewe HL, Cockett AT, Peters PC (2002) Transurethral prostatectomy: Immediate and post-operative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 167:999–1004PubMedCrossRef

Muntener M, Aellig S, Kuettel R, Gehrlach C, Sulser T, Strebel RT (2007) Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcomes. Eur Urol 52(2):510–515PubMedCrossRef

Soderdahl DW, Knight RW, Hansberry KL (1996) Erectile dysfunction following transurethral resection of the prostate. J Uro 156:1354–1356CrossRef

10.

Wasson JH, Reda DJ, Bruskewitz RC, Ellison J, Kelly N (1995) Henderson WG for the Veterans affairs cooperative study group on transurethral resection of the prostate. N Engl J Med 322:75–79CrossRef

11.

Leliefeld HH, Stoevelaar HJ, McDonnell J (2002) Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJUI 89:208–213CrossRef

12.

Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C (2008) Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 ml: a short term prospective randomized trial. Urology 71:247–251PubMedCrossRef

13.

Spaliverio M, Araki M, Culkin DJ, Wong C (2009) Incidence, management and prevention of peri-operative complications of Greenlight HPS laser photoselective vaporization prostatectomy: experience in the first 70 patients. J Endourol 23:495–502CrossRef

14.

Kavoussi PK, Hermans MR (2008) Maintenance of erectile function after photoselective vaporization of the prostate for obstructive benign prostatic hyperplasia. J Sex Med 5:2669–2671PubMedCrossRef

15.

Hamann MF, Naumann CM, van der Horst CS, Junermann KP, Braun PM (2008) Functional outcome following photoselective vaporization of the prostate (PVP): urodynamic findings within 12 months follow-up. Eur Urol 54:902–910PubMedCrossRef

16.

Te AE, Malloy TR, Stein BS, Ulchaket JC, Nseyo UO, Hai MA, Malek RS (2004) Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12 month results from the first United States multi-center prospective trial. J Urol 172:1404–1408PubMedCrossRef

17.

Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ (2006) KTP laser versus transurethral resection: early results of a randomized trial. J Endo Urol 20:580–585

18.

Malek RS, Kuntzman RS, Barrett DM (2005) Photoselective potassium titanyl phosphate laser vaporization of the benign obstructive prostate: observations on long term outcomes. J Urol 174:1344–1348PubMedCrossRef

19.

Stovsky MD, Griffiths RI, Duff SB (2006) A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. J Urol 176:1500–1506PubMedCrossRef

20.

Spaliviero M, Strom KH, Gu X, Araki M, Culkin D, Wong C (2010) Does greenlight HPS laser photoselective vaporization prostatectomy affect sexual function? J Endourol 24(12):2051–2057PubMedCrossRef

21.

Bruyère F, Puichaud A, Pereira H, Faivre d’Arcier B, Rouanet A, Floc’h AP, Bodin T, Brichart N (2010) Influence of photoselective vaporization of the prostate on sexual function: results of a prospective analysis of 149 patients with long-term follow-up. Eur Urol 58:207–211PubMedCrossRef

22.

Andersson KE (2003) Erectile physiology and pathophysiology pathways involved in erectile dysfunction. J Urol 170:S6–S14PubMedCrossRef

23.

Guven EO, Balbay MD, Mete K, Serefoglu EC (2009) Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol 41:287–292PubMedCrossRef

Titel: Sexual function outcome following photoselective vaporisation of the prostate
verfasst von: Tania A. Hossack
Henry H. Woo
Publikationsdatum: 01.04.2012
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 2/2012
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-011-0029-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction

Objective

Material and Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Intravenous dexmedetomidine for treatment of intraoperative penile erection

Effects of micronised purified flavonoid fraction on pain, semen analysis and scrotal color Doppler parameters in patients with painful varicocele; results of a randomized placebo-controlled study

The primary arteriovenous fistula failure—a comparison between diabetic and non-diabetic patients: glycemic control matters

Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness

Finasteride for treatment of refractory hemospermia: prospective placebo-controlled study

The management of chronic kidney disease and end-stage renal disease in Nigeria